One-off Johnson & Johnson COVID-19 vaccine is ineffective against the Delta variant

BREAKING NEWS: One-shot Johnson & Johnson COVID-19 Vaccine Is INFFECTIVE Against Indian ‘Delta’ Variant, Study Suggests

  • Antibody levels in people who received Johnson & Johnson’s COVID-19 vaccine were low against Indian ‘Delta’ coronavirus variant
  • This suggests that the 13 million Americans who received J&J need boosters to protect themselves from variants

The Johnson & Johnson COVID-19 vaccine is ineffective against India’s ‘Delta’ coronavirus variant, a new study suggests.

Researchers found that the antibody levels of people who received the one-time vaccine were much lower compared to those who received the two doses of Pfizer-BioNTech or Moderna vaccines.

The findings add to the growing body of evidence that the 13 million Americans who received J&J will need boosters to protect themselves against highly contagious strains.

In testimony before the Senate Committee on Health, Education, Labor and Pensions on Wednesday, Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), that the Delta variant is responsible for 83 percent of COVID-19 cases.

In the study, which has not been peer-reviewed, blood samples from patients vaccinated with the three approved shots were tested against the variant.

Researchers found that antibody levels in J&J patients were five to seven times lower when exposed to the Delta variant.

In comparison, levels in Pfizer and Moderna patients were three times lower.

The findings are consistent with a UK study, which found that the AstraZeneca vaccine – which is made with the same technology that the J&J vaccine uses – is 33 percent effective against symptomatic diseases caused by Delta.

‘The message we wanted to give was not that people shouldn’t get the J.&J. vaccine, but we hope in the future it will be boosted with a new dose of J&J or a boost with Pfizer or Moderna,” said lead author Dr. Nathaniel Landau, a virologist at NYU’s Grossman School of Medicine. The New York Times.

Antibody levels in people who received Johnson & Johnson’s COVID-19 vaccine were low against the Indian variant of the ‘Delta’ coronavirus. Pictured: Johnson & Johnson’s Covid-19 vaccines seen on a table in Los Angeles, May 2021

This is a latest news item and will be updated.

Advertisement

.